Lung Cancer, Non-small Cell Lung Cancer
Conditions
Brief summary
Lung cancer is responsible for one of the highest incidences of cancer-related mortality globally, and non-small cell lung cancer (NSCLC) accounts for the biggest subtype of lung cancer. In recent years, the use of immunotherapy has revolutionised the management of NSCLC, with better response rates and survival outcomes reported in the literature, compared to traditional cytotoxic chemotherapy. Despite this, doubts remain regarding the true efficacy of immunotherapy in patients \> 75 years old, given that this age subgroup is mis-represented in prospective phase III trials, in terms of numbers and baseline functional status, compared to real-world experience. Furthermore, the use of immune checkpoint inhibitors (ICIs) is associated with a spectrum of immune-related adverse events (irAEs), affecting a range of organ systems. Once again, there are doubts about the safety of the use of these agents in patients \> 75 years old, and whether baseline performance status and comorbidities are good predictors of efficacy and safety outcomes in this elderly patient subgroup. Comprehensive Geriatric Assessment (CGA) and the vulnerable elders survey (VES-13) are assessment tools that provide a good indication of functional status in elderly patients, in a similar capacity to performance status and comorbidities. This study therefore aims to prospectively examine patients \> 70 years old with a diagnosis of NSCLC, commencing immunotherapy. It will assess CGA and VES-13 scores at baseline, and correlate this with certain outcomes such as the incidence of severe adverse effects from immunotherapy at 3 and 6 months, any admissions to hospital arising from immunotherapy toxicities (and the subsequent length of inpatient stay), and mortality within 30 days. In doing so, it will help to determine if CGA and VES-13 scores can be used as a reliable indication of possible future efficacy and toxicity outcomes in this elderly patient subgroup.
Interventions
OTHERQuestionnaires about symptoms
The CGA and VES-13 questionnaires will be conducted at baseline. Immune-related adverse events (irAEs) will be investigated at 3 and 6 months using a Patient Knows Best symptom tracker form (local Trust created).
Sponsors
Hull University Teaching Hospitals NHS Trust
University of Hull
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
70 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients ≥70 years old with advanced NSCLC due to start first or second line ICI therapy. 2. Patients able to give informed consent.
Exclusion criteria
1. Patients already on treatment with ICIs. 2. Patients with CNS or leptomeningeal spread / disease progression. 3. ECOG performance status III/IV. 4. Patients with severe autoimmune diseases. 5. Patients who are recruited and then stop treatment after receiving ≤3 cycles of ICI therapy, secondary to disease progression.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Grading of irAEs at 6 months. | At 6 months after entering the study. |
| Nature of irAEs at 3 months. | At 3 months after entering the study. |
| Grading of irAEs at 3 months. | At 3 months after entering the study. |
| Incidence of irAEs at 6 months. | At 6 months after entering the study. |
| Nature of irAEs at 6 months. | At 6 months after entering the study. |
| Incidence of irAEs at 3 months. | At 3 months after entering the study. |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of re-admission into hospital at 6 months. | At 6 months after entering the study. |
| Duration of inpatient stay (conditional on re-admission into hospital). | Up to 12 months after entering the study. |
| Death within 30 days (if applicable). | Within 30 days of entering the study. |
| Incidence of re-admission into hospital at 3 months. | At 3 months after entering the study. |
Countries
United Kingdom
Outcome results
None listed